JP2021080296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021080296A5 JP2021080296A5 JP2021033324A JP2021033324A JP2021080296A5 JP 2021080296 A5 JP2021080296 A5 JP 2021080296A5 JP 2021033324 A JP2021033324 A JP 2021033324A JP 2021033324 A JP2021033324 A JP 2021033324A JP 2021080296 A5 JP2021080296 A5 JP 2021080296A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- cancer
- composition according
- selective
- need
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 18
- 108091006735 SLC22A2 Proteins 0.000 claims 13
- 102100032417 Solute carrier family 22 member 2 Human genes 0.000 claims 13
- 239000003112 inhibitor Substances 0.000 claims 11
- 229910052697 platinum Inorganic materials 0.000 claims 9
- 206010029350 Neurotoxicity Diseases 0.000 claims 8
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 8
- RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 231100000228 neurotoxicity Toxicity 0.000 claims 8
- 230000007135 neurotoxicity Effects 0.000 claims 8
- OWYLAEYXIQKAOL-UHFFFAOYSA-N 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone Chemical group COC1=CC(OC)=CC(OC)=C1C(=O)CCCN1CCCC1 OWYLAEYXIQKAOL-UHFFFAOYSA-N 0.000 claims 7
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 6
- 206010025323 Lymphomas Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 210000003236 esophagogastric junction Anatomy 0.000 claims 6
- 206010017758 gastric cancer Diseases 0.000 claims 6
- 201000010536 head and neck cancer Diseases 0.000 claims 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims 6
- 201000005202 lung cancer Diseases 0.000 claims 6
- 208000020816 lung neoplasm Diseases 0.000 claims 6
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 6
- 201000011549 stomach cancer Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 229960001415 buflomedil Drugs 0.000 claims 4
- 229960002542 dolutegravir Drugs 0.000 claims 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010029155 Nephropathy toxic Diseases 0.000 claims 2
- 206010033109 Ototoxicity Diseases 0.000 claims 2
- 108091006744 SLC22A1 Proteins 0.000 claims 2
- 102100032416 Solute carrier family 22 member 1 Human genes 0.000 claims 2
- 102100036929 Solute carrier family 22 member 3 Human genes 0.000 claims 2
- 101710102693 Solute carrier family 22 member 3 Proteins 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 231100000417 nephrotoxicity Toxicity 0.000 claims 2
- 230000007694 nephrotoxicity Effects 0.000 claims 2
- 231100000262 ototoxicity Toxicity 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 210000001044 sensory neuron Anatomy 0.000 claims 1
- 210000000273 spinal nerve root Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193529P | 2015-07-16 | 2015-07-16 | |
| US62/193,529 | 2015-07-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521498A Division JP6851639B2 (ja) | 2015-07-16 | 2016-07-15 | プラチナ薬剤の毒性の予防方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021080296A JP2021080296A (ja) | 2021-05-27 |
| JP2021080296A5 true JP2021080296A5 (enExample) | 2021-07-08 |
| JP7117797B2 JP7117797B2 (ja) | 2022-08-15 |
Family
ID=57757682
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521498A Expired - Fee Related JP6851639B2 (ja) | 2015-07-16 | 2016-07-15 | プラチナ薬剤の毒性の予防方法 |
| JP2021033324A Active JP7117797B2 (ja) | 2015-07-16 | 2021-03-03 | プラチナ薬剤の毒性の予防方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521498A Expired - Fee Related JP6851639B2 (ja) | 2015-07-16 | 2016-07-15 | プラチナ薬剤の毒性の予防方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11197862B2 (enExample) |
| EP (2) | EP3322414B1 (enExample) |
| JP (2) | JP6851639B2 (enExample) |
| CN (1) | CN108024986A (enExample) |
| CA (1) | CA2990686A1 (enExample) |
| WO (1) | WO2017011816A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6851639B2 (ja) * | 2015-07-16 | 2021-03-31 | ゾミクス バイオファーマ， インコーポレイテッド | プラチナ薬剤の毒性の予防方法 |
| KR101859922B1 (ko) * | 2017-02-07 | 2018-05-21 | 주식회사 온코크로스 | 클로페네신을 포함하는 대장암 증식 및 전이 억제용 조성물 |
| CN109596818B (zh) * | 2018-12-13 | 2024-03-19 | 丁蓉 | 一种基于电生理学分析当归四逆汤预防奥沙利铂神经毒性机制的研究方法 |
| US20220125877A1 (en) * | 2019-07-10 | 2022-04-28 | Sun Yat-Sen University | Method for treating colorectal cancer |
| JP7583027B2 (ja) * | 2019-08-16 | 2024-11-13 | パーデュー・リサーチ・ファウンデーション | プロテアソームのコア粒子の低分子刺激物質 |
| CN111067894A (zh) * | 2020-01-14 | 2020-04-28 | 广东药科大学 | 咪康唑在制备抗肺鳞癌药物和顺铂增敏剂中的应用 |
| CN111110675A (zh) * | 2020-02-25 | 2020-05-08 | 浙江大学 | 延胡索乙素在制备抗奥沙利铂外周神经毒性药物中的应用 |
| CN113527333B (zh) * | 2020-04-13 | 2022-08-05 | 南开大学 | 具有生物活性的度鲁特韦衍生物及其制备方法和应用 |
| JP7504367B2 (ja) | 2021-05-18 | 2024-06-24 | 株式会社Ｌｔｔバイオファーマ | 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009032172A2 (en) * | 2007-08-31 | 2009-03-12 | Massachusetts Institute Of Technology | Platinum compositions as treatment for oct-related cancers |
| EP2090311A1 (en) * | 2008-02-18 | 2009-08-19 | Laboratorios Del. Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy |
| KR20110008166A (ko) | 2008-02-18 | 2011-01-26 | 라보라토리오스 델 드라. 에스테브.에스.에이. | 화학요법의 결과로 발생하는 신경병적 통증의 치료를 위한 시그마 수용체 리간드에 결합하는 화합물들의 용도 |
| EP3485908B1 (en) | 2009-10-16 | 2021-08-18 | Mereo BioPharma 5, Inc. | Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents |
| WO2013178763A1 (en) * | 2012-05-30 | 2013-12-05 | Sensorion | Methods for treating vestibulotoxicity |
| CA2891855A1 (en) | 2012-12-21 | 2014-06-26 | Sykehuset Sorlandet Hf | Egfr targeted therapy of neurological disorders and pain |
| JP6851639B2 (ja) * | 2015-07-16 | 2021-03-31 | ゾミクス バイオファーマ， インコーポレイテッド | プラチナ薬剤の毒性の予防方法 |
-
2016
- 2016-07-15 JP JP2018521498A patent/JP6851639B2/ja not_active Expired - Fee Related
- 2016-07-15 EP EP16825297.1A patent/EP3322414B1/en active Active
- 2016-07-15 WO PCT/US2016/042673 patent/WO2017011816A1/en not_active Ceased
- 2016-07-15 US US15/744,485 patent/US11197862B2/en active Active
- 2016-07-15 CA CA2990686A patent/CA2990686A1/en active Pending
- 2016-07-15 CN CN201680053118.8A patent/CN108024986A/zh active Pending
- 2016-07-15 EP EP20198351.7A patent/EP3777851B1/en active Active
-
2021
- 2021-03-03 JP JP2021033324A patent/JP7117797B2/ja active Active
- 2021-12-06 US US17/543,504 patent/US20220202823A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021080296A5 (enExample) | ||
| JP2015519329A5 (enExample) | ||
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| JP2008530248A5 (enExample) | ||
| JP2011511071A5 (enExample) | ||
| HRP20131083T1 (hr) | POSTUPCI PRIMJENE N-(5-terc-BUTILIZOKSAZOL-3-IL)-N'-{4-[7-(2-MORFOLIN-4-ILETOKSI)IMIDAZO[2,1-b][1,3]BENZOTIAZOL-2-IL]FENIL}UREE U LIJEÄŚENJU PROLIFERATIVNE BOLESTI | |
| JP2019516733A5 (enExample) | ||
| JP2017533220A5 (enExample) | ||
| JP2020523356A5 (enExample) | ||
| JP2020523359A5 (enExample) | ||
| JP2020523354A5 (enExample) | ||
| JP2024056875A (ja) | 疼痛を処置するためにフェノキシプロピルアミン化合物を使用する方法 | |
| RU2018126829A (ru) | Применение производных хинолина для лечения рака пищевода, а также способ лечения, фармацевтическая композиция и набор с их использованием | |
| CN102438608A (zh) | 包含ave8062和索拉非尼的抗肿瘤组合 | |
| JP2016507500A5 (enExample) | ||
| JP2014534229A5 (enExample) | ||
| JP2021504384A5 (enExample) | ||
| JP2020536048A5 (enExample) | ||
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| JP2020520385A5 (enExample) | ||
| JPWO2021260111A5 (enExample) | ||
| JP2015510945A5 (enExample) | ||
| Yagoubian et al. | Nicotine nasal spray as an adjuvant analgesic for third molar surgery | |
| JP2018506549A5 (enExample) | ||
| CN110638802A (zh) | Atca在制备治疗肿瘤的药物中的用途 |